ALPMY News and Press, Astellas Pharma Inc. ADR From 04/13/22

European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer PR Newswire - Enfortumab vedotin is the first medicine approved in the EU for patients who received a prior platinum-containing chemotherapy and a PD...

Astellas Announces Topline 12-week Results from Phase 3 Study of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Women in Asia PR Newswire Astellas' MOONLIGHT 1 TM clinical trial evaluating investigational fezolinetant 30 mg administered once da...

Astellas looks posed to exit a period of prolonged weak revenue growth and see acceleration into the mid-to-high single-digits on multiple product/indication approvals. Xtandi will remain the lead drug for the foreseeable future, but compounds for menopausal vasomotor symptoms, bladde...

Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY) said fezolinetant met a main goal of a phase 3 trial evaluating the oral, nonhormonal compound to treat vasomotor symptoms associated with menopause. VMS, commonly called hot flashes or flushes and night sweats are common symptoms of ...

Astellas Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolinetant which Inform Future Regulatory Filings for the Treatment of Vasomotor Symptoms Associated with Menopause PR Newswire TOKYO , March 7, 2022 /PRNewswire/ -- Astellas Pharma ...

Vancouver, Kelowna, Delta, BC - February 28, 2022 (Investorideas.com Newswire) Investorideas.com ( www.investorideas.com ), a global investor news source covering Artificial Intelligence (AI) brings you today's edition of The AI Eye - watching stock news, deal tracker and advancemen...

Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer PR Newswire TOKYO and BOTHELL, Wash. , Feb. 28, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, P...

Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy - Late-breaking data from Cohort H of EV-103 trial to be presented at the 2022 ASCO Genitourinary Cancer...

Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease - Data presented at the 18th Annual WORLDSymposiumTM 2022 - PR Newswire TOKYO , Feb. 7, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, Presid...

Astellas Pharma (OTCPK:ALPMY): 9M Non-GAAP core basic EPS of ¥91.57, compared to ¥89.71 in the first nine months of FY2020. Revenue of ¥992.29B (+5.5% Y/Y). Outlook: For further details see: Astellas Pharma reports 9M results